Needle-free vaccines Jurata is actively pursuing needle-free mRNA vaccine delivery using thin film technology, presenting a potential sales angle for partners in vaccine distribution, cold-chain reductions, and rapid deployment solutions.

Room-temperature stability Recent CEPI collaboration to develop wafer-like, room-temperature-stable mRNA films opens opportunities to sell storage and logistics services, including regional distribution, supply chain optimization, and emergency stockpiling for governments and NGOs.

Funding momentum The company has attracted multi-million seed and grant funding, signaling investor confidence and potential for scalable partnerships, licensing deals, or co-development agreements with larger biotech firms.

Manufacturing simplification Jurata’s focus on removing cold storage and expediting manufacturing suggests opportunities to cross-sell manufacturing services, contract development, and process optimization to biotech and pharmaceutical manufacturers seeking resilient supply chains.

Industry partnerships Active collaborations with CEPI and Blue Knight initiatives indicate a strong network presence; target outreach to public health agencies, global health initiatives, and impact-focused investors seeking scalable vaccine delivery platforms.